Skip to main content

Table 2 Summary of safety outcomes at week 16

From: Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis

Trial (author)

Year

Treatment arms

Treatment-emergent adverse events, % (n/N)

Death, % (n/N)

Discontinuation due to adverse events, % (n/N)

Non-severe infections, % (n/N)

Serious adverse events, % (n/N)

MEASURE-1 (Baeten) [25]

2015

SEC

68.3 (170/249)

0 (0/249)

1.2 (3/249)

30.1 (75/249)

2.0 (5/249)

 

PBO

55.7 (68/122)

0.8 (1/122)

4.1 (5/122)

12.3 (15/122)

4.1 (5/122)

MEASURE-2 (Baeten) [25]

2015

SEC

61.4 (89/145)

0.7 (1/145)

4.8 (7/145)

31.7 (46/145)

5.5 (8/145)

 

PBO

63.5 (47/74)

0 (0/74)

5.4 (4/74)

27.0 (20/74)

4.1 (3/74)

MEASURE-3 (Pavelka) [26]

2017

SEC

45.3 (68/150)

0 (0/150)

0 (0/150)

N/A

0.7 (1/150)

 

PBO

44 (33/75)

0 (0/75)

0 (0/75)

N/A

1.3 (1/75)

MEASURE-4 (Kivitz) [27]

2018

SEC

56.2 (131/233)

0 (0/233)

1.3 (3/233)

N/A

1.7 (4/233)

 

PBO

54.7 (64/117)

0 (0/117)

0.9 (1/117)

N/A

3.4 (4/117)

COAST-V (van der Heijde) [28]

2018

IXE

42.7 (70/164)

0 (0/164)

1.8 (3/164)

20.1 (33/164)

1.2 (2/164)

 

PBO

39.5 (34/86)

0 (0/86)

0 (0/86)

15.1 (13/86)

0 (0/86)

COAST-W (Deodhar) [29]

2019

IXE

62.3 (132/212)

0.5 (1/212)

6.1 (13/212)

26.9 (57/212)

3.3 (7/212)

 

PBO

49.0 (51/104)

0 (0/104)

1.9 (2/104)

9.6 (10/104)

4.8 (5/104)

  1. SEC secukinumab, IXE ixekizumab, PBO placebo, N/A not applicable